Guideline for prevention of RhD alloimmunization in RhD negative women
Authors:
M. Lubušký 1,2; M. Procházka 1; O. Šimetka 3; I. Holusková 4
Authors place of work:
Porodnicko-gynekologická klinika LF UP a FN Olomouc, přednosta doc. MUDr. Radovan Pilka, Ph. D.
1; Ústav lékařské genetiky a fetální medicíny LF UP a FN Olomouc, přednosta prof. MUDr. Jiří Šantavý, CSc.
2; Porodnicko-gynekologická klinika FN Ostrava, přednosta MUDr. Ondřej Šimetka
3; Transfúzní oddělení FN Olomouc, přednosta MUDr. Dana Galuszková, Ph. D., MBA
4
Published in the journal:
Ceska Gynekol 2010; 75(4): 323-324
Summary
Events following which anti-D immunoglobulin should be given to all RhD negative women with no anti-D antibodies: First trimester indications (50 μg) - termination of pregnancy, spontaneous abortion followed by instrumentation, ectopic pregnancy, chorionic villus sampling, partial molar pregnancy; Second and third trimester indications (100 μg) – amniocentesis, cordocentesis, other invasive prenatal diagnostic or therapeutic procedures, spontaneous or induced abortion, intrauterine fetal death, attempt at external cephalic version of a breech presentation, abdominal trauma, obstetric haemorrhage; Antenatal prophylaxis at 28th weeks of gestation (250 μg); Delivery of an RhD positive infant * (100 μg); Minimal dose: before 20 weeks gestation - 50 μg (250 IU), after 20 weeks gestation ** - 100 μg (500 IU); Timing: as soon as possible, but no later than 72 hours after the event. In cases where prevention of RhD alloimmunization is not performed within 72 hours of a potentially sensitising event, it is still reasonable to administer anti-D immunoglobulin (IgG anti-D) within 13 days, and in special cases, administration is still recommended up to a maximum interval of 28 days postpartum.; FMH (fetomaternal haemorrhage) - If the amount of fetal erythrocytes which entered the maternal circulation is quantitatively determined, administration of 10 μg IgG anti-D per 0.5 ml of fetal erythrocytes or 1 ml of whole blood is indicated.
*also if the RhD type of the infant has not been determined or is in doubt, **in conjunction with a test to assess the volume of any fetomaternal hemorrhage.
Zdroje
1. Ľubušký, M. Prevence RhD aloimunizace. Evidence Based Medicine a přehled doporučených postupů. Postgrad Med, 2010, 12 (2), s. 194-198.
2. Ľubušký, M. Prevence Rh (D) aloimunizace u Rh (D) negativních žen. Prakt Gyn, 2008, 12 (2), s. 100-103.
3. Ľubušký, M., Procházka, M., Krejčová, L., et al. Prevence Rh (D) aloimunizace u Rh (D) negativních žen v těhotenství a po porodu Rh (D) pozitivního dítěte. Čes Gynek, 2006, 71 (3), s. 173-179.
Štítky
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineČlánok vyšiel v časopise
Czech Gynaecology
2010 Číslo 4
Najčítanejšie v tomto čísle
- Shoulder dystocia during vaginal delivery
- Repair of the 3rd and 4th degree obstetric perineal tear
- Perinatal brachial plexus palsy
- Complications of radical oncogynecological operations